Caplyta generic
Caplyta, an antipsychotic medication, is owned by Intra-Cellular Therapies, Inc. The drug's active ingredient is lumateperone tosylate. The drug was first authorized for market use on December 20, 2019. Caplyta holds a total of 16 patents, none of which have expired to date. The drug is only available in capsule form, administered orally.
When will Caplyta generic be available?
As for the availability of Caplyta generics, the last patent for Caplyta will expire on December 10, 2040, after which point generic versions of the drug may start to appear. However, drug patent challenges against Caplyta can be filed starting from December 21, 2023.
Caplyta uses
The manufacturing company markets Caplyta for the treatment of bipolar depression and schizophrenia. The effectiveness of Caplyta in treating these disorders is brought about by the modulation of 5-hydroxytryptamine 2 receptor activities. lumateperone tosylate, the active ingredient in Caplyta, aids in treating schizophrenia by mediating the 5-HT2A receptor, serotonin transporter, and dopamine D1/D2 signaling pathways. Similarly, it is used to treat bipolar type I disorder, bipolar type II disorder, and bipolar depression. Caplyta can also improve the residual symptoms of schizophrenia.
Caplyta patent expiration
Caplyta currently holds 16 active patents, the last of which is set to expire on December 10, 2040. The first patent challenges may begin appearing from December 21, 2023. The generics for Caplyta are expected to become available shortly after the expiration of the last patent. Below is the details of the patents: